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Arterial stiffness in predialysis patients with uremia.
Background. Hemodialysis patients have advanced arterial
wall stiffening as shown by increased aortic pulse wave velocity
(PWV), an independent predictor of cardiovascular mortality.
We compared aortic PWV of uremic patients before starting
hemodialysis treatment with that of patients on maintenance
hemodialysis.
Methods. The subjects were 71 patients with end-stage re-
nal disease (ESRD) before starting hemodialysis (predialysis
group), 144 patients on maintenance hemodialysis, and 140
healthy control subjects. These three groups were all nondia-
betic and comparable in age and gender.
Results. The hemodialysis group had greater aortic PWV than
the healthy subjects, and the predialysis patients showed a still
higher value than the hemodialysis group. Multiple regression
analysis in the total subjects revealed that the presence of re-
nal failure was significantly associated with increased aortic
PWV independent of age, gender, blood pressure, body mass
index, smoking, high-density lipoprotein (HDL) and nonhigh-
density lipoprotein (non-HDL) cholesterol levels. In contrast,
hemodialysis was associated with decreased aortic PWV inde-
pendent of renal failure and the other factors. Further analyses
in the combined uremic patients again indicated the favorable
impact of hemodialysis on aortic PWV independent of the clas-
sical risk factors, use of antihypertensive medications, including
angiotensin-converting enzyme inhibitors and calcium channel
blockers, hematocrit, serum calcium, phosphorus, parathyroid
hormone levels, and the use of calcium carbonate. Insulin re-
sistance using homeostasis model assessment (HOMA-IR) was
associated with increased aortic PWV.
Conclusion. Aortic stiffening was present in uremic patients
before starting hemodialysis treatment and no adverse effect
of hemodialysis was observed, suggesting the important roles
of renal failure and/or metabolic alterations secondary to renal
failure in arterial stiffness in patients with uremia.
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Cardiovascular disease is a major cause of death in
patients with end-stage renal disease (ESRD) treated
with hemodialysis, and their risk relative to the general
population exceeds 10 for death from cardiovascular dis-
ease [1]. Also, hemodialysis patients have advanced ar-
terial wall changes as shown by increased thickness of
carotid artery [2] and increased stiffness of aorta [3, 4].
Recent studies showed that these morphologic [5, 6] and
functional properties [7,8] of arterial wall are predic-
tors of death from cardiovascular disease in hemodial-
ysis populations independent of the classical risk
factors.
So far, it is not established whether hemodialysis treat-
ment promotes these arterial wall changes, although
Lindner et al [9] speculated that long-term hemodialy-
sis accelerated atherosclerosis. Most of previous cross-
sectional studies showed no significant relationship of
duration of hemodialysis with histologic grading [10],
thickness [2, 11], or stiffness [3, 4] of arterial wall
of patients on maintenance hemodialysis. In addition,
hemodialysis duration did not associate with the risk of
death from cardiovascular disease [7, 8]. Recently, Joki
et al [12] reported that significant stenosis of coronary
arteries is frequently found in uremic patients at the time
of starting hemodialysis. Muntner et al [13] showed that
the risk of cardiovascular mortality is elevated in patients
with chronic renal insufficiency. Mourad et al [14] found
that increased arterial stiffness is significantly associated
with reduced creatinine clearance in subjects with mild-
to-moderate renal failure. These studies indicate that
arterial wall change is advanced and the risk of cardio-
vascular death is elevated before starting hemodialysis,
although these studies did not examine the possible ef-
fects of hemodialysis. We [11] recently found that carotid
artery intima-media thickness of predialysis patients was
as great as that of maintenance hemodialysis patients, and
that the presence of renal failure, but not hemodialysis,
was a significant risk factor for the arterial thickening. To
date, no previous study performed comparison of arterial
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Table 1. Subjects
Healthy Predialysis Hemodialysis P value
Number 140 71 144 —
Male gender 59 (42%) 41(58%) 69 (47%) 0.100
Age years 60 ± 10 61 ± 13 60 ± 9 0.590
Smoker 44 (31%) 31 (44%) 40 (28%) 0.062
Body mass index kg/m2 22.6 ± 2.7 21.7 ± 3.4 21.4 ± 2.5a 0.001
Systolic blood pressure mm Hg 128 ± 17 143 ± 23a 153 ± 26a,b <0.0001
Diastolic blood pressure mm Hg 79 ± 11 81 ± 13 84 ± 14a 0.005
Total cholesterol mg/dL 211 ± 29 162 ± 43a 168 ± 40a <0.0001
HDL cholesterol mg/dL 62 ± 20 39 ± 12a 40 ± 13a <0.0001
Non-HDL cholesterol mg/dL 149 ± 31 122 ± 42a 128 ± 40a <0.0001
Triglycerides mg/dL 97 (45–424) 97 (27–248) 113 (33–378) 0.062
Fasting glucose mg/dL 96 ± 12 88 ± 10a 79 ± 12a,b <0.0001
Insulin lU/mL 5.0 (2.0–26) 8.6 (1.0–25) 6.8 (2–20) <0.0001
HOMA-IR 0.97(0.39–6.93) 1.62 (0.18–6.17) 1.23 (0.34–4.59) <0.0001
Serum creatinine mg/dL 0.9 ± 0.2 10.0 ± 3.4a 11.5 ± 1.8a,b <0.0001
Serum calcium mg/dL — 8.7 ± 1.2 9.4 ± 0.9 <0.0001
Serum phosphorus mg/dL — 6.6 ± 1.8 6.0 ± 1.4 0.0125
Calcium × phosphorus — 52.3 ± 16 55.6 ± 14 0.125
Intact parathyroid hormone pg/mL — 282 (10–788) 132 (10–1900) 0.0003
C-reactive protein mg/dL — 0.4 (0.1–5.2) 0.4 (0.1–5.4) 0.641
Hematocrit % — 24.9 ± 4.6 27.3 ± 4.2 0.0002
Serum albumin g/dL 3.2 ± 0.5 3.7 ± 0.6 <0.0001
Medication for hypertension — 61 (86%) 64 (54%) <0.0001
Use of ACE inhibitors — 9 (13%) 21 (15%) 0.468
Use of calcium channel blockers — 56 (79%) 53 (37%) <0.0001
Use of calcium carbonate — 16 (23%) 109 (76%) <0.0001
Presence of vascular complications — 8 (11%) 28 (19%) 0.131
Duration of hemodialysis years — — 7.5 ± 5.4 —
Abbreviations are: HDL, high-density lipoprotein; non-HDL, non-high-density lipoprotein; HOMA-IR, insulin resistance index by homeostasis model assessment;
ACE, angiotensin-converting enzyme.
Data are percentage, mean ± SD, and median (range). P values are by chi-square test, analyses of variance (ANOVA), and Kruskal-Wallis test, respectively.
aP < 0.05 vs. healthy control subjects; bP < 0.05 vs. predialysis group by Scheffe-type multiple comparison.
stiffness between predialysis and hemodialysis patients
with ESRD.
The purpose of the present study was to compare
arterial stiffness between predialysis and hemodialysis
patients, and to evaluate the factors affecting arterial stiff-
ness in patients with uremia.
METHODS
Subjects
This study consisted of 355 subjects including 71
patients with chronic renal failure just before start-
ing hemodialysis treatment (predialysis group), 144
patients with ESRD treated with maintenance hemodial-
ysis (hemodialysis group), and 140 healthy control sub-
jects. We randomly selected these subjects from our
database after categorizing by age and gender, so that
the three groups were comparable in age and gender. In-
formation was compiled from the questionnaire about
smoking habits and past history of vascular diseases, in-
cluding coronary artery, cerebrovascular, and peripheral
artery diseases. Clinical characteristics of the subjects
were given in Table 1. Informed consent was obtained
from all study participants. This study was approved by
the Institutional Ethical Committee.
Patients in the predialysis group were those with ESRD
entering hemodialysis treatment. All measurements were
done 1 to 3 days before their first hemodialysis ses-
sion. The primary renal diseases of the predialysis group
were chronic glomerulonephritis (59%), hypertensive
nephrosclerosis (14%), polycystic disease (8%), toxemia
of pregnancy (3%), chronic pyelonephritis (1%), sys-
temic lupus erythematodes (1%), and unknown (14%).
We excluded patients who had been diagnosed to have
diabetes mellitus on the basis of past history and/or
presence of overt fasting hyperglycemia of 126 mg/dL
or greater [15]. Medication for hypertension included
calcium channel blockers (79%), angiotensin-converting
enzyme (ACE) inhibitors (13%), a-, b- or ab-receptor
antagonists (30%), and loop diuretics (25%). Of the pre-
dialysis patients, 86% received antihypertensive medica-
tion. Statins were used for 3% of the predialysis patients
for dyslipidemia. These patients were studied without
washing out these medications.
Patients in the hemodialysis group were those who
were on maintenance hemodialysis for more than three
months. The hemodialysis patients received 3 to 5
hours of hemodialysis, three times a week, using bi-
carbonate dialysate. Dialyzer membranes were cupro-
phane (54%), polymethylmethacrylate (26%), cellu-
lose triacetate (18%), and ethylenevinyl alcohol (3%).
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The primary renal diseases of the hemodialysis group
were chronic glomerulonephritis (72%), hypertensive
nephrosclerosis (5%), polycystic disease (9%), toxemia
of pregnancy (3%), chronic pyelonephritis (2%), gout
(2%), systemic lupus erythematodes (2%), and unknown
(7%). We excluded diabetic patients using the same cri-
teria as above [15]. Medication for hypertension included
calcium channel blockers (42%), ACE inhibitors (17%),
a-, b- or ab-receptor antagonists (6%), and loop di-
uretics (24%). Of the hemodialysis patients, 54% re-
ceived antihypertensive medication. Statins were used
for 3% of the hemodialysis patients for dyslipidemia.
These patients were studied without washing out these
medications.
The healthy control subjects were participants of a
local health check program at the Osaka Municipal
Health Promotion Center. We excluded subjects with
overt hyperglycemia using the same criteria as above [15],
overt proteinuria, and liver dysfunction as defined by in-
creased serum alanine aminotransferase (ALT) >50 IU.
Those on medication for diabetes mellitus, hypertension,
and/or hyperlipidemia were also excluded. Therefore, the
healthy control subjects included those who were hyper-
tensive and/or hyperlipidemic without medication.
Blood pressure and aortic pulse wave velocity
(PWV) measurement
Blood pressure and aortic PWV measurements were
made with the patients in a supine position after a
5-minute bed rest. In hemodialysis patients, these mea-
surements were performed 1 to 2 hours after hemodial-
ysis to avoid possible effects of volume overload before
dialysis and to reduce acute hemodynamic changes just
after dialysis. Blood pressure was measured with a mer-
cury sphygmomanometer and a standard cuff in the arm.
The average of two blood pressure measurements was
recorded.
Aortic PWV was measured as a noninvasive index
of aortic sclerosis [16] by the method of Hasegawa
[17], using a PWV meter (model PWV-200) (Fukuda
Denshi, Tokyo, Japan) as previously described [4, 8].
Briefly, amorphous sensors were put on the skin at right
femoral and left carotid arteries to record pulse waves.
Heart sounds S1 and S2 were detected by a microphone
set on the right edge of the sternum at the second in-
tercostals space. Electrocardiogram was monitored with
electrodes placed on the right and left arms and right leg.
The PWV meter measures time intervals between pulse
waves at the carotid and femoral sites (T) and between
S2 and the notch of carotid pulse wave (Tc). PWV of the
aorta was calculated as follows:
PWV[m/s] = 1.3L/(T + Tc)
where L is the measured distance in meter between the
heart sound microphone and the femoral probe. The ac-
tual distance between the aortic orifice and the femoral
artery was estimated to be 1.3 L [17]. T + Tc indicates
the time in second for the pulse waves to travel from the
aortic orifice to the femoral artery. PWV measurements
were done for five consecutive pulses, and the average
was used for analysis. The interobservation variation (co-
efficient of variation) was less than 5%.
Blood sampling and assays
Blood was drawn in the morning after an overnight
fast of at least 12 hours. In patients with hemodialy-
sis treatment, fasting blood was taken at least 44 hours
after the previous dialysis session. Serum albumin, cal-
cium, phosphorus, C-reactive protein, and intact parathy-
roid hormone (PTH) were measured in the predialysis
and hemodialysis patients. Whole blood was used for
hematocrit, ethylenediaminetetraacetic acid (EDTA)-
plasma for glucose, insulin and lipids, and serum for other
biochemical assays. Glucose was measured by a glucose
oxidase method. Insulin was measured by radioimmuno-
metric assay (RIA) (Dinabot Co., Tokyo, Japan). To-
tal cholesterol was measured enzymatically. High-density
lipoprotein (HDL) cholesterol was measured after
precipitating apolipoprotein B-containing lipoproteins
with dextran sulfate and magnesium. Non-high-density
lipoprotein (non-HDL) cholesterol was calculated
by subtracting HDL cholesterol from total cholesterol.
Other measurements were by routine methods.
Assessment of insulin resistance using homeostasis
model assessment (HOMA-IR) index
Insulin resistance was evaluated using the HOMA-IR
index originally described by Matthews et al [18].
HOMA-IR was calculated using the following formula:
HOMA-IR = fasting glucose(mmol/L)
× fasting insulin(lU/mL)/22.5
HOMA-IR correlated closely with the insulin sensitiv-
ity index by the standard euglycemic hyperinsulinemic
clamp as shown by Matthews et al [18] and by us [19].
This index can be used in subjects with renal failure [20].
Statistical analysis
Data were summarized as percentage, mean ± SD, and
median (range). Difference in prevalence was evaluated
by chi-squared test. Difference between mean values was
assessed by analysis of variance (ANOVA), and then post
hoc test was performed by Scheffe-type multiple compar-
ison. Median (range) was given for triglycerides, insulin,
HOMA-IR, C-reactive protein, and intact PTH because
of their skewed distribution. Difference in median values
was assessed by Mann-Whitney test or Kruskal-Wallis
test. These variables with skewed distribution were
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Fig. 1. Aortic pulse wave velocity (PWV)
of the healthy, predialysis, and hemodialy-
sis groups. Data are mean ± standard devi-
ation. Numbers in each column indicate the
number of subjects. ∗P < 0.01 vs. healthy
control group; ∗∗P < 0.001 vs. healthy con-
trol group; #P < 0.05 vs. hemodialysis group
by Scheffe-type multiple comparison. Differ-
ence between the predialysis and hemodialy-
sis groups was significant in comparison where
the subjects were not stratified by age.
entered to univariate and multivariate regression models
after log-transformation. Correlation between two vari-
ables was examined by linear regression analysis. Mul-
tiple regression analysis was used to assess independent
associations between one dependent and two or more
independent variables. Dummy variables were used for
gender (female = 0, male = 1), presence of renal failure
(no = 0, yes = 1), hemodialysis (nonhemodialysis = 0,
hemodialysis = 1), smoking (nonsmoker = 0, smoker =
1), and antihypertensive medications (no = 0, yes = 1).
P values less than 0.05 were considered significant. All
these analyses were performed using statistics software
for Windows (StatView 5) (SAS Institute Inc., Cary, NC,
USA) on personal computers.
RESULTS
Comparison of aortic PWV among the three groups
Figure 1 shows aortic PWV of the three groups. As
compared with the healthy group (7.4 ± 1.4 m/second),
the predialysis group (9.7 ± 2.4 m/second, P = 0.001)
and the hemodialysis group (8.9 ± 2.0 m/second, P <
0.0001) had a significantly greater aortic PWV. In age-
categorized comparison, the increased aortic PWV in the
hemodialysis group remained significant in the 30 to 49,
50 to 59, and 60 to 69 years, but not in the 70 to 79 years.
The increased aortic PWV of the predialysis group was
significant in all age ranges.
When compared between the predialysis and
hemodialysis groups, aortic PWV was significantly
greater in the predialysis group (P = 0.001). The dif-
ference between the predialysis and the hemodialysis
groups were not significant when the subjects were
divided into age categories.
Correlation between aortic PWV and other factors
Factors affecting aortic PWV were examined by simple
regression analysis (Table 2). In the total subjects, aortic
PWV correlated positively with age, systolic blood pres-
sure, diastolic blood pressure, insulin (log-transformed),
and HOMA-IR (log-transformed), and negatively with
HDL cholesterol. In the healthy control group, aortic
PWV correlated positively with age, systolic blood pres-
sure, diastolic blood pressure, non-HDL cholesterol, and
fasting glucose. Aortic PWV correlated only with age in
the predialysis group. In the hemodialysis group, it cor-
related positively with age, systolic blood pressure, and
total cholesterol, negatively with serum calcium. In the
combined group of patients with chronic renal failure
(predialysis + hemodialysis), aortic PWV correlated pos-
itively with age and systolic blood pressure, and patients
taking antihypertensive medications had a higher aortic
PWV than the other patients.
Independent factors associated with aortic PWV
Factors independently associated with aortic PWV
were examined by using multiple regression models in
the total subjects (Table 3). In the first model, includ-
ing classical risk factors, PWV was associated positively
with age and systolic blood pressure and negatively with
HDL cholesterol. In model 2, to which the presence of
renal failure was added, the presence of renal failure was
shown as a significant factor associated with aortic PWV
independent of the above factors. In model 3, includ-
ing hemodialysis as an additional variable, the associa-
tion of renal failure with increased aortic PWV remained
significant, while hemodialysis treatment had a signifi-
cant association with decreased aortic PWV. In addition
to these, aortic PWV had significant and independent
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Table 2. Simple regression analysis of factors correlating with aortic pulse wave velocity (PWV)
Variables Total Healthy Predialysis Hemodialysis Hemodialysis + Predialysis
Age 0.383c 0.471c 0.540c 0.286c 0.402c
Male gender 0.042 0.028 −0.024 −0.019 −0.003
Smoking −0.022 −0.030 −0.055 −0.070 −0.033
Body mass index −0.098 0.048 −0.099 −0.028 −0.049
Systolic blood pressure 0.356c 0.385c 0.176 0.236b 0.173a
Diastolic blood pressure 0.141b 0.270b −0.083 0.103 0.021
Log (triglycerides) 0.063 0.106 −0.018 0.222 0.093
HDL cholesterol −0.262c −0.047 −0.135 0.015 −0.047
Non-HDL cholesterol −0.003 0.267b 0.010 0.165 0.092
Fasting glucose −0.067 0.307c 0.031 0.041 0.099
Log (insulin) 0.196c 0.078 −0.049 0.095 0.055
Log (HOMA-IR) 0.165b 0.125 −0.043 0.101 0.075
Serum creatinine 0.345c 0.079 −0.150 −0.002 −0.124
Serum calcium — — 0.069 −0.172a −0.130
Serum phosphorus — — 0.021 −0.068 −0.014
Calcium × phosphorus — — 0.003 −0.128 −0.072
Log (intact parathyroid hormone) — — −0.087 −0.002 0.009
Log (C-reactive protein) — — 0.159 0.098 0.131
Hematocrit — — 0.106 −0.096 −0.064
Medication for hypertension% — — 0.049 0.179 0.188b
Duration of hemodialysis — — — −0.113 —
Abbreviations are: HDL, high-density lipoprotein; Non-HDL, non-high-density lipoprotein; HOMA-IR, insulin resistance index by homeostasis model assessment.
aP < 0.05; bP < 0.01; cP < 0.001.
Table 3. Multiple regression analysis of factors affecting aortic pulse
wave velocity (PWV) in the total subjects (N = 355)
Model 1 Model 2 Model 3
Age 0.359b 0.386b 0.367b
Male gender 0.087 0.098 0.096
Smoking −0.019 −0.018 −0.034
Systolic blood pressure 0.330b 0.202a 0.243b
Diastolic blood pressure −0.026 0.013 −0.006
Non-HDL cholesterol 0.067 0.137a 0.150a
HDL cholesterol −0.189b 0.005 0.007
Body mass index −0.071 −0.020 −0.024
Presence of renal failure — 0.357b 0.488b
Hemodialysis — — −0.213b
R2 0.320b 0.381b 0.405b
Abbreviations are: HDL, high-density lipoprotein; R2, multiple coefficient of
determination.
The table gives standard regression coefficients (b values).
aP < 0.01; bP < 0.001.
associations with age, systolic blood pressure, and non-
HDL cholesterol in this model.
Association of aortic PWV with uremia-related factors
The above results showed the associations of the pres-
ence of renal failure and hemodialysis treatment with
increased and decreased aortic PWV, respectively. To ex-
amine a possibility that the latter finding was confounded
by other factors relating renal failure and hemodialysis,
we further analyzed the data using multivariate models
in the predialysis and hemodialysis groups (Table 4). In
model 1, containing classic risk factors and hemodialysis
treatment, hemodialysis was again shown as a significant
factor associated with decreased aortic PWV.
Because the predialysis and hemodialysis groups were
significantly different in the use of antihypertensive med-
Table 4. Multiple regression analysis of factors affecting aortic pulse
wave velocity (PWV) in patients with renal failure (N = 215)
Model Model Model Model Model Model
1 2 3 4 5 6
Age 0.405c 0.416c 0.409c 0.418c 0.444c 0.417c
Male gender 0.033 0.072 0.038 0.028 −0.004 0.060
Smoking −0.022 −0.017 −0.019 −0.021 −0.023 0.037
Systolic blood 0.244c 0.219c 0.246c 0.229c 0.247c 0.280c
pressure
Non-HDL 0.135a 0.148a 0.132a 0.115 0.140a 0.115
cholesterol
HDL −0.023 −0.039 −0.010 −0.024 −0.008 −0.049
cholesterol
Body mass index −0.021 −0.027 −0.022 −0.031 −0.040 −0.070
Hemodialysis −0.198b −0.216b −0.201b −0.170a −0.234c −0.171a
Medication for — 0.050 — — — —
hypertension
Hematocrit — — −0.004 — — —
Serum calcium — — — 0.001 — —
Serum — — — 0.049 — —
phosphorus
Log (intact — — — 0.002 — —
parathyroid
hormone)
Serum creatinine — — — — 0.118 —
Log (HOMA-IR) — — — — — 0.147a
R2 0.265c 0.288c 0.270c 0.241c 0.274c 0.291c
Abbreviations are: HDL, high-density lipoprotein; Non-HDL, non-high-
density lipoprotein; HOMA-IR, insulin resistance index by homeostasis model
assessment; R2, multiple coefficient of determination.
The negative impact of hemodialysis on aortic PWV was significant in model
1. Then, possible confounding factors were evaluated in the subsequent models.
The table gives standard regression coefficients (b values).
aP < 0.05; bP < 0.01; cP < 0.001.
ications, hematocrit, parameters of calcium homeosta-
sis, serum creatinine, and the index of insulin resistance,
these variables were added as uremia-related variables
in the subsequent analyses (models 2 to 6). HOMA-IR
was a significant and independent factor associated with
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aortic PWV, whereas other uremia-related factors did
not show significant association with aortic PWV. Impor-
tantly, hemodialysis treatment remained a significant fac-
tor associated with decreased aortic PWV in all of these
models. Also, the positive associations of age and systolic
blood pressure remained significant. The positive asso-
ciation between non-HDL cholesterol and aortic PWV
was significant in models 1, 2, 3, and 5. Further analyses
indicated that aortic PWV had no significant association
with the use of ACE inhibitors, calcium channel blockers,
or calcium carbonate. A phosphate binder sevelamer was
not available in Japan at the time of this study. Also, aor-
tic PWV did not have significant association with serum
albumin or C-reactive protein levels (data not shown).
DISCUSSION
In the present study, we compared aortic PWV be-
tween predialysis and hemodialysis patients to evaluate
the effects of renal failure and hemodialysis on artery
wall stiffness. These two groups had a significantly greater
aortic PWV than the healthy subjects. The mean aortic
PWV of the predialysis group was higher than that of
the hemodialysis group. Multiple regression analyses re-
vealed that aortic PWV had a positive association with
the presence of renal failure and a negative association
with hemodialysis treatment independent of other fac-
tors. Further analyses indicated that blood pressure, non-
HDL cholesterol, and HOMA-IR as independent factors
associated with aortic PWV of the renal failure patients.
These results suggest that it is not hemodialysis but re-
nal failure and/or uremia-related metabolic abnormali-
ties that have adverse effects on aortic stiffness.
Although, a recent study [13] has shown an increased
risk of cardiovascular death in patients with chronic re-
nal insufficiency, there is only limited amount of informa-
tion about the arterial wall changes in predialysis patients
with chronic renal failure. Bonomini et al [21] previously
reported that the longer the duration of uremia on low
protein diet, the worse were the clinical and metabolic
problems of atherosclerosis, suggesting the role of re-
nal failure in atherosclerosis. In our recent study [11],
we found that predialysis patients had increased carotid
artery intima-media thickness. Joki et al [12] reported a
high prevalence of significant coronary artery stenosis in
patients starting hemodialysis. These studies indicate the
presence of morphologic alterations in arterial wall in
predialysis patients. Mourad et al [14] found an inverse
correlation between aortic PWV and creatinine clearance
in subjects with mild-to-moderate renal failure. In the
present study, we showed a remarkable increase in aortic
PWV in uremic patients just before starting hemodial-
ysis. Thus, this study provides further evidence that the
functional property of arterial wall is impaired not only
in hemodialysis patients but also in predialysis patients
with renal failure.
Our results indicated the associations of renal failure
and hemodialysis with increased and decreased aortic
PWV, respectively. There are several possibilities that ex-
plain this finding. First, the result might have been con-
founded by some factors that differed between these two
groups in the baseline comparison. To rule out this possi-
bility, we reanalyzed the data by using multivariate mod-
els that included the use of antihypertensive medications,
including ACE inhibitors [22] and calcium channel block-
ers [23], hematocrit, parameters of calcium homeostasis,
the use of phosphate binders [24], and an index of in-
sulin resistance HOMA-IR as covariates. However, the
association between treatment with hemodialysis and de-
creased aortic PWV remained significant.
Second, volume overload may be an important factor
for aortic PWV. Guerin et al [25] reported in maintenance
hemodialysis patients treated for more than 3 months
that aortic PWV was not always decreased after achiev-
ing blood pressure control by “dry weight” adjustment
and antihypertensive medications in their long-term ob-
servation. Studies on an effect of acute volume control
[22, 26] failed to find a significant change in aortic PWV
following a single session of hemodialysis. However, the
lack of change in aortic PWV may be the result of vol-
ume reduction and electrolyte changes counteracted by
neural and hormonal responses. In the present study, we
measured aortic PWV 1 to 2 hours after dialysis, when the
conditions were expected to be more stable than just af-
ter hemodialysis, although such measurements may not
be representative of steady state. Therefore, we cannot
rule out a possibility that volume control by hemodialy-
sis explains the seemingly favorable association between
hemodialysis and aortic PWV found in this study.
Third, plasma lipids may explain the change in arterial
stiffness. This study confirmed a positive link between
aortic PWV and non-HDL cholesterol that was shown
in our previous study [4]. Both aortic PWV [7, 8] and
non-HDL cholesterol [27] are significant predictors of
cardiovascular mortality in hemodialysis patients. How-
ever, non-HDL cholesterol was not different between the
predialysis and hemodialysis groups in the present study,
and the association between aortic PWV and non-HDL
cholesterol was independent of the presence of renal fail-
ure and hemodialysis treatment. These results suggest
that non-HDL lipoproteins have a significant role in arte-
rial stiffness regardless of hemodialysis, but they are not
likely to explain the negative association between aortic
PWV and hemodialysis.
Fourth, the change in insulin resistance may account
for the change in PWV in uremic patients. HOMA-IR is
a surrogate index for insulin resistance measured by the
euglycemic glucose clamp, the gold standard method
for insulin resistance [18]. We previously showed that
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HOMA-IR correlated closely with the measurement by
glucose clamp in patients with type 2 diabetes mellitus
[19] and in those with chronic renal failure [20]. We also
showed an elevated HOMA-IR as an independent pre-
dictor of cardiovascular mortality in hemodialysis pa-
tients [28]. Insulin resistance is known to correlate with
carotid artery stiffness in patients with type 2 diabetes
mellitus [29]. Also, aortic PWV in elderly individuals
correlates with plasma triglyceride and 2-hour post-load
glucose levels [30]. These studies suggest the link among
insulin resistance, arterial stiffness, and increased risk for
cardiovascular mortality in these high-risk populations.
In this study, HOMA-IR, in parallel with aortic PWV,
was the highest in the predialysis group, the lowest in the
healthy subjects, and intermediate in the hemodialysis pa-
tients. DeFronzo et al [31] showed that insulin resistance
in uremic patients was partly reversed by hemodialysis.
Therefore, insulin resistance appears to have an impor-
tant role in arterial wall stiffening in uremia, although it
may not fully explain the seemingly favorable effect of
hemodialysis on aortic PWV.
Fifth, the association between hemodialysis and aor-
tic PWV may be related to other factors not measured
in this study such as advanced glycation end products
(AGEs), homocysteine, and asymmetrical dimethyl argi-
nine (ADMA). These substances are known to accumu-
late in uremic plasma [32–34], to affect vascular functions
[35–37], and to be reduced by hemodialysis [32, 33, 37].
Finally, the cross-sectional design may have brought
some bias in this study. Because we [8] and others [7] have
shown that increased aortic PWV is a predictor of cardio-
vascular death in hemodialysis patients, it is possible that
hemodialysis patients with very high PWV had already
died and the hemodialysis patients of this study were
“survivors.” Such a possible selection bias can explain
the seemingly favorable effect of hemodialysis on aortic
PWV. However, this kind of bias would be present not
only in the hemodialysis but also the predialysis patients
with uremia. In addition, even a longitudinal observation
of PWV change in the course of maintenance hemodial-
ysis treatment will not be able to distinguish the effects
of uremia, hemodialysis, and aging, because the subjects
are exposed to these factors similarly. Therefore, it is quite
difficult to clearly separate the effects of renal failure and
hemodialysis on the vascular change. Nonetheless, it is a
novel and important finding that uremic patients with-
out hemodialysis had a comparable or even higher aortic
PWV than those on maintenance hemodialysis.
CONCLUSION
We showed that uremic patients before starting
hemodialysis had significantly increased aortic PWV as
well as those on maintenance hemodialysis. The risk fac-
tor analyses indicated the important roles of renal failure
and/or renal failure-related metabolic changes in arterial
stiffening of uremic patients. Further studies are needed
to determine whether hemodialysis treatment has favor-
able effects on arterial stiffness and how we can improve
arterial stiffness to reduce the risk of cardiovascular death
in patients with uremia.
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